Summit Therapeutics Share Discussion Threads

[lagosboy] 27/1/2019 12:39

Very little value is being attributed to its C-Diff drug and nor has it ever been, despite it being a very good drug.

One has to question why as Summit has been around for some time and has a presence both in the UK and the much larger US bio-investor market. I have given my reasons before.

My biggest problem is with Glyn , his treatment of shareholders at Antisoma was appalling and the the way DMD went up in smoke with normal timetables for AGM's being moved was also concerning.

I think he knew well in advance as why invest £10 m is Discuva's paltform and move into the gonorrhoea space if he was truly confident about the DMD and C-Diff programs. I am not sure if it will add any value and clearly there was a seller prepared to divest for just £10m.



I retain a small residual holding now but have very little confidence that Summ will ever produce any significant shareholder value. The mergence of our US White Knight rather than giving me hope unfortunately does the opposite. Once the US vultures arrive its normally time for shareholders to leave but hopefully I am wrong about that.

[kirk 6] 27/1/2019 12:16

Fair comment that lago agree with most of that! Very surprised this is not trading much higher now but things take time so going end of Q1 we are much higher

[lagosboy] 26/1/2019 08:38

Its not an analysts opinion its a statement of facts

Summit Therapeutics plc (NASDAQ:SMMT)’s earnings per share has been growing at a 0 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at 0 percent while most common profitability ratio return on investment (ROI) was 0 percent. The company’s institutional ownership is monitored at 17.94 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.

The second link does include an opinion based upon historical facts.

Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.

[football] 25/1/2019 23:01

Analyst Opinion Summary: Summit Therapeutics plc (SMMT), Christopher & Banks Corporation (CBK)








Present Performance: Summit Therapeutics (NASDAQ: SMMT)

[algernon2] 25/1/2019 20:44

I still like Glyn and still have confidence in him.

[lagosboy] 25/1/2019 12:26

The impending antibiotic resistance crises has been widely known about and covered for almost a decade now.

I would be inclined to invest at these levels but keep having to ask the question as to why there has been no positive impact on the stock whatsoever?

Is it the fear of Govt intervention, wafer thin margins, huge R&D costs and a limited drug due to further resistance as bacteria and fungi develop the ability to defeat the new drugs designed to kill them.

Glyn has attended every conference on the planet over the last few years with no impact whatsoever - he needs to step aside and hopefully our new major investor will quickly recognise his failings.

[algernon2] 25/1/2019 11:19

Destiny Pharma up 13% after being mentioned in dispatches yesterday.Shame Summit was not mentioned,especially as we both share a certain David Roblin.
To Summit David is C.O.O and C.M.O. whilst to Destiny he is on the Scientific Advisory Board.
As Michael Caine might say: "I did not know this".
Synergy for the future as they appear to have their own antibiotic discovery platform similar maybe to Discuva?!

[nobbygnome] 25/1/2019 08:39

Summit are presenting at a Proactive Investor event on 7th Feb....

[kirk 6] 24/1/2019 21:14

Shouldn't this have an extremely positive impact on the stock ?

[football] 24/1/2019 21:12

Antimicrobial resistance: UK launches 5-year action plan and 20-year vision
The plans outline the UK's contribution to containing and controlling antimicrobial resistance (AMR) in health, animals, the environment and the food chain.

[chrisatrdg] 24/1/2019 16:21

UK government to pump millions into antibiotics research for superbug fight (Good article)



YY proactive YC investors

[kirk 6] 24/1/2019 09:07

We have a massive market here and now funded we should see this re rate

[football] 24/1/2019 08:56

This is where we need the company to start ringing up or stirring up some interest in this antibiotic trials with the media.



By the way anyone watch the big build on the BBC last night? Shame summits DM trials collapsed last year as it would of made a real difference to their lives and fellow sufferers

[kirk 6] 24/1/2019 08:51

Antibiotics resistance on the radio We are in prime position here

[nobbygnome] 24/1/2019 08:38

>> waterloo post 24676

Just about the first time ever I agree with something you have posted 😜.....

[chrisatrdg] 24/1/2019 08:34

Hi waterloo01 - Very good point - there has been some good Buying this morning hopefully we will have a 'Blue day' today.Regards.

[waterloo01] 24/1/2019 08:17

Could make all the difference in pharma valuing antibiotics!

[chrisatrdg] 24/1/2019 08:15

Hi All - This mornings news as shown by waterloo01 & football must surely be good news for Summit which may slowly creep into the current share price Its taken the Government some time to recognise the antibiotic resistance problem but good that it now has.

[football] 24/1/2019 08:07

Drug firms get millions for war on superbugs

First new class of antibiotics in four decades

[waterloo01] 24/1/2019 06:48

The drugs advisory body, the National Institute for Health and Clinical Excellence, and NHS England will also trial a new payment model that means pharmaceutical companies will be paid for drugs based on how valuable the medicines are to the NHS, rather than by the quantity of drugs sold.

[kirk 6] 22/1/2019 21:49

Bloody hell the price shot up to 1.6p post close that's up over 10%

[kirk 6] 22/1/2019 21:23

Would actually of closed up if it printed again bid 43 offer 47 (up on day). Holding these break 30p shorty